09:38 AM EST - BioVaxys Technology Corp. : Announced today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company's questions regarding bioproduction and clinical development plans for its planned pivotal Phase III study for its T-cell immune response diagnostic for SARS-CoV-2. The FDA has stated that the Written Response will be available by July 23 , 2021. BioVaxys Technology Corp.
shares C.BIOV are trading unchanged at $0.26.
